Verrica Pharmaceuticals buy Brookline Capital Management
Start price
18.12.25
/
50%
€0.58
Target price
18.12.26
€14.48
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 18.12.26. The prediction end date can be changed by Brookline_Capital_Ma at any time.Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Verrica Pharmaceuticals | - | - |
| iShares Core DAX® | -3,51 % | -8,75 % |
| iShares Nasdaq 100 | -2,78 % | -0,63 % |
| iShares Nikkei 225® | -2,04 % | -6,84 % |
| iShares S&P 500 | -2,60 % | -2,23 % |
Comments by Brookline_Capital_Ma for this prediction
In the thread Discuss Verrica Pharmaceuticals
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
Ratings data for VRCA provided by MarketBeat